Potential diagnostic biomarkers for chronic kidney disease of unknown etiology (CKDu) in Sri Lanka: a pilot study.

Abstract

BACKGROUND:

In Sri Lanka, there exists chronic kidney disease of both known (CKD) and unknown etiologies (CKDu). Identification of novel biomarkers that are customized to the specific causative factors would lead to early diagnosis and clearer prognosis of the diseases. This study aimed to find genetic biomarkers in blood to distinguish and identify CKDu from CKD as well as healthy populations from CKDu endemic and non-endemic areas of Sri Lanka.

METHODS:

The expression patterns of a selected panel of 12 potential genetic biomarkers were analyzed in blood using RT-qPCR. Fold changes of gene expressions in early and late stages of CKD and CKDu patients, and an apparently healthy population of a CKDu endemic area, Girandurukotte (GH) were calculated relative to apparently healthy volunteers from a CKDu non-endemic area, Kandy (KH) of Sri Lanka, using the comparative CT method.

RESULTS:

Significant differences were observed between KH and early stage CKDu for both the insulin-like growth factor binding protein 1 (IGFBP1; p = 0.012) and kidney injury molecule-1 (KIM1; p = 0.003) genes, and KH and late stage CKD and CKDu for the glutathione-S-transferase mu 1 (GSTM1; p < 0.05) gene. IGFBP1 and KIM1 genes showed significant difference between the early and late stage CKDu (p < 0.01). The glutamate cysteine ligase catalytic subunit (GCLC) gene had significantly different expression between KH and all the other study groups (p < 0.01). The GH group was significantly different from the KH group for the oxidative stress related genes, G6PD, GCLC and GSTM1 (p < 0.01), and also the KIM1 gene (p = 0.003). IGFBP1, insulin-like growth factor binding protein 3 (IGFBP3), fibronectin 1 (FN1) and KIM1 showed significant correlations with serum creatinine, and IGFBP1, KIM1 and kallikrein 1 (KLK1) with eGFR (p < 0.05).

CONCLUSION:

A panel consisting of IGFBP1, KIM1, GCLC and GSTM1 genes could be used in combination for early screening of CKDu, whereas these genes in addition with FN1, IGFBP3 and KLK1 could be used to monitor progression of CKDu. The regulation of these genes has to be studied on larger populations to validate their efficiency for further clinical use.

• Authors: Saravanabavan Sayanthooran, Dhammika N Magana-Arachchi, Lishanthe Gunerathne, Tilak Abeysekera
• Journal: BMC nephrology (BMC Nephrol) Vol. 18 Issue 1 Pg. 31 (Jan 19 2017) ISSN: 1471-2369 [Electronic] England
• PMID: 28103909 (Publication Type: Journal Article)

Chemical References

• Biomarkers
• HAVCR1 protein, human
• Hepatitis A Virus Cellular Receptor 1
• IGFBP1 protein, human
• Insulin-Like Growth Factor Binding Protein 1
• Glutathione Transferase
• glutathione S-transferase M1
• EGFR protein, human
• ErbB Receptors
• GCLC protein, human
• Glutamate-Cysteine Ligase

Topics

• Biomarkers (blood)
• ErbB Receptors (blood)
• Feasibility Studies
• Female
• Glutamate-Cysteine Ligase (blood)
• Glutathione Transferase (blood)
• Hepatitis A Virus Cellular Receptor 1 (blood)
• Humans
• Insulin-Like Growth Factor Binding Protein 1 (blood)
• Male
• Middle Aged
• Pilot Projects
• Prevalence
• Renal Insufficiency, Chronic (blood, diagnosis, epidemiology)
• Reproducibility of Results
• Risk Factors
• Sensitivity and Specificity
• Sri Lanka (epidemiology)